The Path to Clearance Starts with Smart Predicate Strategy

The Hidden Risk in Your Regulatory Strategy

In our experience, many sponsors don’t realize there’s an issue until they’re already deep into validation or responding to FDA questions. Predicate device selection is often viewed as one of the first regulatory steps in preparing a 510(k) submission, but in reality, it is one of the most strategic.

The right predicate does more than support a substantial equivalence argument. It helps define the regulatory pathway, informs study design, shapes intended use positioning, and can significantly influence the efficiency of FDA review. The wrong predicate can quietly expand your validation scope, introduce avoidable clinical work, or even put your 510(k) pathway at risk.

At Arete, we view predicate strategy as a critical early-stage decision that should be approached with both regulatory insight and operational foresight.

What Expert CRO Support Looks Like

A knowledgeable CRO partner brings more than familiarity with cleared devices. Effective support requires a deep understanding of FDA precedent, evolving submission expectations, technological comparability, and the downstream impact on analytical and clinical validation activities. It also requires understanding where FDA is likely to push back, before you commit to studies.

Key Questions to Ask Early

Early strategic questions should include:

How closely does the intended use align beyond wording, including patient population, specimen type, and clinical context?
Are the technological characteristics truly comparable including assay design, detection method, and result output?
Where do meaningful differences exist?
What data will be required to support those differences and how will that impact your validation timeline and cost?

For IVDs in particular, small differences that seem manageable early such as specimen type, cutoff values, or result interpretation, can significantly increase analytical or clinical study expectations later.

Addressing these questions early helps sponsors build a stronger, more defensible submission strategy and can reduce avoidable delays during review.

The Downstream Impact of Predicate Strategy

In practice, an ineffective predicate strategy can create downstream challenges that extend well beyond the regulatory submission itself. Misalignment in intended use, technological characteristics, or performance claims may lead to expanded verification and validation requirements, additional clinical evidence requests, or multiple rounds of Agency questions during review. We often see this show up as unexpected study expansion or repeated FDA questions that trace back to early predicate decisions.

These issues can directly impact development timelines, increase overall program costs, and delay time to market.

This is particularly important for sponsors developing novel diagnostics, platform technologies, or new biomarker assays. In some cases, a more strategic early assessment can help determine whether a 510(k) is viable, or whether another regulatory pathway should be considered before significant investment is made.

A strategic CRO partner should support this process through a structured evaluation of the regulatory landscape, including review of cleared predicate devices, comparison of labeling and claims, assessment of technological similarities and differences, and identification of the analytical and clinical data required to support substantial equivalence.

How to Build a Stronger Submission from the Start

The most successful FDA submissions begin long before the first document is assembled. They begin with a thoughtful regulatory framework grounded in experience, precedent, and a clear understanding of how the Agency is likely to evaluate the device.

As FDA expectations continue to evolve, predicate selection remains a dynamic strategic exercise rather than a static administrative task. Sponsors that invest early in a well-informed predicate strategy are often better positioned for more efficient submissions and smoother review pathways.

A strong CRO partnership helps ensure that predicate selection is not treated as a checkbox, but as a strategic component of the path to clearance.

If you're early in development and unsure whether your predicate strategy will hold up under FDA scrutiny, it's worth pressure-testing it sooner rather than later.

We’re always happy to review your current approach and identify potential risks before they become costly delays.

‍